Roche moves to acquire PathAI for up to $1.05 billion in major AI pathology push
The acquisition positions Roche more aggressively in digital pathology and precision diagnostics capabilities
The acquisition positions Roche more aggressively in digital pathology and precision diagnostics capabilities
Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence
The initial consideration for the transaction is US$ 12 million
Subscribe To Our Newsletter & Stay Updated